Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission
暂无分享,去创建一个
Yi-Kuang Chuang | B. Ko | M. Yao | Chien-Yuan Chen | Liang-In Lin | Yuan-Yeh Kuo | Jih-Luh Tang | H. Tien | H. Hou | W. Chou | S. Hsu | Shang-Ju Wu | Feng-Ming Tien | Jia-Hau Liu | Cheng-Hong Tsai | X. Liao | Chia‐Wen Liu | Mei‐Hsuan Tseng | Ming‐Chih Liu | Mei-Fang Hou | Yen-Ling Peng | Sheng-Chuan Huang | Yu-Sin Wu | F. Tien | Yen-Ling Peng | M. Yao | H. Hou
[1] C. Bloomfield,et al. Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. , 2019, Blood.
[2] S. Asthana,et al. Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. , 2019, Cancer discovery.
[3] M. Konopleva,et al. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3‐internal tandem duplication genotypes , 2018, Cancer.
[4] J. Kanda,et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. , 2018, Blood advances.
[5] Hong-jie Shen,et al. Impact of FLT3-ITD length on prognosis of acute myeloid leukemia , 2018, Haematologica.
[6] B. Ko,et al. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor‐risk factor in de novo acute myeloid leukemia patients , 2018, European journal of haematology.
[7] B. Ko,et al. Concomitant WT1 mutations predict poor prognosis in acute myeloid leukemia patients with double mutant CEBPA , 2018, Haematologica.
[8] Chieh-Yu Liu,et al. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome , 2018, Blood Cancer Journal.
[9] M. Levis,et al. How I treat FLT3-mutated AML. , 2017, Blood.
[10] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[11] Claude Preudhomme,et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.
[12] B. Ko,et al. Genetic alterations and their clinical implications in older patients with acute myeloid leukemia , 2016, Leukemia.
[13] N. Schmitz,et al. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] Chieh-Yu Liu,et al. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia , 2016, Oncotarget.
[15] L. Bullinger,et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. , 2014, Blood.
[16] Bor-Sheng Ko,et al. Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. , 2014, Leukemia research.
[17] R. Hills,et al. Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. , 2014, Blood.
[18] Chieh-Yu Liu,et al. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution , 2014, American journal of hematology.
[19] B. Ko,et al. Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome , 2014, Blood Cancer Journal.
[20] J. Esteve,et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. , 2013, Blood.
[21] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[22] M. Caligiuri,et al. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. , 2012, Blood.
[23] J. Esteve,et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Angelo J. Canty,et al. Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.
[25] T. Haferlach,et al. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia , 2011, Leukemia.
[26] Y. Chao,et al. Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] Torsten Haferlach,et al. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Chieh-Yu Liu,et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. , 2009, Blood.
[29] Svetlana K. Eden,et al. Immortal time bias in critical care research: Application of time-varying Cox regression for observational cohort studies* , 2009, Critical care medicine.
[30] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[31] H. Tien,et al. Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD , 2008, Leukemia.
[32] Adam J Mead,et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.
[33] O. Yli-Harja,et al. Global Gene Expression Profile of Human Cord Blood–Derived CD133+ Cells , 2006, Stem cells.
[34] Chunaram Choudhary,et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. , 2005, Cancer research.
[35] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[36] G. Ehninger,et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia , 2003, Genes, chromosomes & cancer.
[37] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[38] E. Estey,et al. CME Information: Acute myeloid leukemia: 2016 Update on risk-stratification and management , 2016 .
[39] S-J Wu,et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia , 2014, Leukemia.
[40] Chieh-Yu Liu,et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. , 2012, Blood.
[41] Chieh-Yu Liu,et al. Clinical Trials and Observations , 2022 .
[42] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[43] R Simon,et al. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. , 1984, Statistics in medicine.